Lunchbox试验:顺铂联合放疗后卡铂联合紫杉醇对比卡铂联合紫杉醇后放疗再卡铂联合紫杉醇三明治疗法治疗晚期子宫内膜癌的随机III期试验
该随机III期试验比较晚期子宫内膜癌两种序贯治疗策略。48例患者入组,42例符合无效性分析,试验因入组缓慢提前关闭。化疗放疗后化疗组与三明治疗法组3年无复发生存率和总生存率均无显著差异。
要点
- 化疗放疗后化疗组3年无复发生存率85.7%,三明治组73.4%,差异无统计学意义(p=0.58)。
- 化疗放疗后化疗组3年总生存率88.4%,三明治组80.9%,差异无统计学意义(p=0.55)。
- 两组不良事件无显著差异,但试验因入组缓慢提前关闭且把握度不足。
核心结论
- 化疗放疗后化疗与三明治疗法在无复发生存率、总生存率或不良事件方面未观察到显著差异,但试验把握度不足且因入组缓慢提前关闭。
研究设计与样本
- 随机III期试验,入组48例患者来自8个中心,42例符合无效性分析,试验提前关闭,中位随访30.9个月。
主要发现
- 化疗放疗后化疗组3年无复发生存率85.7%(95%CI 62至95),三明治疗法组73.4%(95%CI 43至89),p=0.58。
- 化疗放疗后化疗组3年总生存率88.4%(95%CI 61至97),三明治疗法组80.9%(95%CI 51至93),p=0.55。
关键数值与推荐
- 入组标准为FIGO 2009 III期或IVA期子宫内膜癌,或I期或II期浆液性或透明细胞子宫内膜癌且细胞学阳性。
- 化疗放疗后化疗方案:顺铂50 mg/m2静脉第1天和第29天联合放疗,随后卡铂AUC 5或6联合紫杉醇175 mg/m2每21天4周期。
- 三明治疗法方案:卡铂AUC 6联合紫杉醇175 mg/m2每21天3周期,随后放疗,再卡铂AUC 5或6联合紫杉醇175 mg/m2每21天3周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验把握度不足且因入组缓慢提前关闭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective was to compare sequencing strategies for treatment of advanced endometrial carcinoma. METHODS: Patients were eligible if they had FIGO 2009 Stage III or IVA endometrial carcinoma or Stage I or II serous or clear cell endometrial carcinoma and positive cytology. Patients were randomized to: Cisplatin 50 mg/m2 IV Days 1 and 29 plus radiation followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles (chemoRT then chemo) vs. Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by radiation followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles (sandwich therapy). Futility analysis was planned. The primary objective was to determine if chemoRT then chemo improves recurrence-free survival (RFS) compared to sandwich therapy. RESULTS: Of the 48 patients enrolled at 8 sites, 42 patients were eligible for futility analysis, and the trial was closed early. The median follow-up was 30.9 months. The 3-year RFS was 85.7% (95% confidence interval [CI], 62 to 95) in the chemoRT then chemo arm and 73.4% (95% CI, 43 to 89) in the sandwich therapy group (p = 0.58). The 3-year overall survival (OS) was 88.4% (95% CI, 61 to 97) in the chemoRT then chemo arm and 80.9% (95% CI, 51 to 93) in the sandwich therapy group (p = 0.55). CONCLUSION: There was no observed significant difference between chemoRT then chemo compared to sandwich therapy in terms of RFS, OS, or adverse events, although the trial was underpowered and closed early due to low accrual.
引用
- Barlin JN, Mahar B, Ata A, et al. Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma. Gynecol Oncol. 2023. PMID: 38052110. doi:10.1016/j.ygyno.2023.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。